0NZT Stock Overview A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for UCB Historical stock prices Current Share Price €183.23 52 Week High €189.95 52 Week Low €76.92 Beta 0.33 1 Month Change 2.98% 3 Month Change 11.54% 1 Year Change 136.33% 3 Year Change 83.72% 5 Year Change 154.56% Change since IPO 354.55%
Recent News & Updates
UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa Nov 20
Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024 Nov 15
UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis Oct 01
UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024 Sep 29
First half 2024 earnings released: EPS: €1.10 (vs €1.64 in 1H 2023) Jul 26
UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels Jun 15 See more updates
UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa Nov 20
Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024 Nov 15
UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis Oct 01
UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024 Sep 29
First half 2024 earnings released: EPS: €1.10 (vs €1.64 in 1H 2023) Jul 26
UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels Jun 15
UCB SA, Annual General Meeting, Apr 24, 2025 May 01
Insufficient new directors May 01 UCB SA to Report First Half, 2024 Results on Jul 25, 2024
UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx Apr 04
UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies Mar 09
Full year 2023 earnings released: EPS: €1.81 (vs €2.22 in FY 2022) Feb 29
UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting Dec 04
UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis Nov 15 UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor
UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio Nov 02
UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters Nov 01
UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis Oct 19
UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis Oct 18
UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023 Oct 14
UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa Oct 13
UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024 Aug 01
First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022) Jul 29
Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive Jul 23 UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl
Upcoming dividend of €0.93 per share at 1.5% yield Apr 21
Full year 2022 earnings released: EPS: €2.22 (vs €5.58 in FY 2021) Feb 26
UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis Jan 19
UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023 Jan 10 UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review Jan 07
UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa Dec 10 UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care
UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia Nov 24
UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients Nov 15
UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis Nov 11
UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study Sep 08
First half 2022 earnings released Jul 30 UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2 May 25
UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022 May 24
UCB SA, Annual General Meeting, Apr 27, 2023 May 14
UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis May 12
UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome May 03
Upcoming dividend of €0.91 per share Apr 22
UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome Mar 28
UCB SA, Annual General Meeting, Apr 28, 2022 Feb 22
UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results Feb 05
UCB Announces Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study Jan 22
UCB SA Announces Positive Top-Line Interim Analysis Results Showing That the Phase 3 Be Mobile 1 Study Met the Primary and All Ranked Secondary Endpoints Jan 19
UCB SA Announces Positive Top-Line Interim Analysis Results from the Phase 3 Be Mobile 2 Study Dec 17
UCB Announces Positive Phase 3 Results for Rozanolixizumab in Generalized Myasthenia Gravis Dec 11
First half 2021 earnings released: EPS €3.00 (vs €1.92 in 1H 2020) Aug 01
UCB Announces New Data from Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Women of Childbearing Age Jun 01
Independent Vice Chairman Pierre Gurdjian has left the company May 04
Chairman Diégo du de Bergendal has left the company May 04 Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs
Revenue beats expectations Feb 27
Full year 2020 earnings released: EPS €3.87 (vs €4.22 in FY 2019) Feb 26
New 90-day low: €83.87 Feb 20
UCB Announces Changes on Board of Directors Jan 20
New 90-day low: €84.52 Jan 07
UCB SA to Report First Half, 2021 Results on Jul 29, 2021 Dec 16
doc.ai and UCB Teams Up to Develop Breakthrough Artificial Intelligence Models to Advance Care Nov 20
UCB and Stanford Medicine Establish Multi-Year Collaboration Nov 19
UCB Announces U.S. Food and Drug Administration Approval of VIMPAT Nov 18
UCB SA (ENXTBR:UCB) agreed to acquire Handl Therapeutics from Gemma Frisius Fonds NV. Nov 13
UCB Announces New Data on Its TNF Inhibitor Nov 06
Bimekizumab Phase 3 Data Shows Superior Skin Clearance over Humira® in Moderate-To-Severe Psoriasis Patients Nov 02
New 90-day low: €89.76 Oct 27
New 90-day low: €94.80 Oct 07
UCB Announces That the FDA and EMA Have Accepted the Biologics License Application (BLA) and Marketing Authorization Application (MAA), Respectively, for Bimekizumab for the Treatment of Adults with Moderate to Severe Plaque Psoriasis Sep 24
New 90-day low - €95.80 Sep 15
UCB SA to Report Fiscal Year 2020 Results on Feb 25, 2021 Aug 10 Shareholder Returns 0NZT GB Pharmaceuticals GB Market 7D 0.7% -1.7% -2.6% 1Y 136.3% -3.5% 2.4%
See full shareholder returns
Return vs Market: 0NZT exceeded the UK Market which returned 2.4% over the past year.
Price Volatility Is 0NZT's price volatile compared to industry and market? 0NZT volatility 0NZT Average Weekly Movement 3.8% Pharmaceuticals Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0NZT has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0NZT's weekly volatility (4%) has been stable over the past year.
About the Company Founded Employees CEO Website 1925 9,000 Jean-Christophe Tellier www.ucb.com
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome.
Show more UCB SA Fundamentals Summary How do UCB's earnings and revenue compare to its market cap? 0NZT fundamental statistics Market cap €35.40b Earnings (TTM ) €240.00m Revenue (TTM ) €5.45b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0NZT income statement (TTM ) Revenue €5.45b Cost of Revenue €1.76b Gross Profit €3.70b Other Expenses €3.46b Earnings €240.00m
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 27, 2025
Earnings per share (EPS) 1.27 Gross Margin 67.80% Net Profit Margin 4.40% Debt/Equity Ratio 31.8%
How did 0NZT perform over the long term?
See historical performance and comparison Dividends
0.7% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 21:40 End of Day Share Price 2024/12/20 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources UCB SA is covered by 48 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mark van der Geest ABN AMRO Bank N.V. Kamla Singh AlphaValue Brian Bourdot Barclays
Show 45 more analysts 
